Alzamend Neuro Reports $3.0 Million Net Loss and Increased Assets Amid Clinical Development Progress

Alzamend Neuro, Inc. reported a net loss of $3.0 million for the three months ended July 31, 2026, compared to a net loss of $2.7 million for the same period in 2025, reflecting a 12% increase in losses. The company did not generate any revenue during this period, consistent with its status as a clinical-stage biopharmaceutical firm focused on developing treatments for Alzheimer’s disease and other neuropsychiatric disorders. Total operating expenses rose to $3.0 million, up from $2.7 million year-over-year, driven primarily by a significant increase in general and administrative expenses, which more than doubled to $1.9 million from $959,000.

In terms of financial position, Alzamend's total assets increased to $8.5 million as of July 31, 2026, up from $2.1 million at the end of the previous fiscal period. This growth was largely attributed to a substantial increase in cash reserves, which rose to $7.6 million from $710,689. The company’s stockholders’ equity also improved significantly, reaching $5.8 million compared to $733,211 in the prior period. The increase in cash was primarily due to financing activities, including the issuance of 7,500 shares of Series D Convertible Preferred Stock, which generated $7.5 million.

Operationally, Alzamend has made strides in its clinical development programs. The company is advancing two product candidates: AL001, a treatment for Alzheimer’s and other disorders, and ALZN002, an immunotherapy vaccine for Alzheimer’s. The company has initiated multiple clinical trials for AL001, with positive topline data reported from a Phase IIA trial. Additionally, Alzamend has partnered with Massachusetts General Hospital and Harvard Medical School to conduct imaging clinical trials aimed at assessing lithium levels in the brain, which is a key component of its research strategy.

Despite these advancements, Alzamend continues to face challenges related to its financial sustainability. The company has indicated that it will need to raise additional capital to fund ongoing operations and clinical trials, as it expects to incur losses for the foreseeable future. The management has expressed concerns about its ability to continue as a going concern without securing further financing. The company plans to pursue additional funding through equity and debt financing, which may impact existing shareholders' rights and holdings.